Received Jul 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Y020301 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | Z003766 | — |
No additional AE reported; FBE stated patient should have received MMR II and VARIVAX; This spontaneous report was received from a nurse and refers to a 12-month-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 19-Jun-2025, the patient was inadvertently administered with a dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Z003766, expiration date: 30-Jan-2027), dose number 1 (anatomical location and administration route were not reported) and with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y020301, expiration date: 09-Jun-2026), dose number 1, (anatomical location and administration route were not reported) administered during their wellness visit as prophylaxis. It was stated that the patient should have received Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) and Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live lyophilisate and solvent for solution for injection (M-M-R II), instead of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD). No side effects were reported.